OnCo
institutionsInstitution

TROG Cancer Research

aka Trans Tasman Radiation Oncology Group, TROG

The Australian and New Zealand radiation oncology trials group, which has run practice-changing trials of hypofractionation, stereotactic radiotherapy and radiation-drug combinations.

Founded in 1989 as the Trans Tasman Radiation Oncology Group and based in Newcastle, New South Wales, TROG is the cooperative group for radiation oncology across Australia and New Zealand. TROG 96.01 established short-course androgen deprivation with radiotherapy for locally advanced prostate cancer, CHISEL (TROG 09.02) showed stereotactic ablative radiotherapy beats conventional radiotherapy in inoperable early lung cancer, and TROG 12.01 tested de-escalation with cetuximab in HPV-positive oropharyngeal cancer. It co-ran PORTEC-3 in endometrial cancer and runs quality-assurance programmes for radiotherapy trials. TROG partners with ANZUP, AGITG and Breast Cancer Trials on multimodality studies.

Location
Newcastle, NSW, AU
Type
consortium
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#226 · 26 points (0 Newsweek + 0 NCI + 26 from 13 linked objects) · ranking

Programmes

4top
  • Prostate radiotherapy and androgen deprivation (TROG 96.01, RADAR)
  • SABR for early lung cancer (CHISEL)
  • HPV-positive head and neck de-escalation
  • Radiotherapy quality assurance

Connected

13top

Pages like this

not linked directly; found by shared links